PPAR-g агоністи: чи рішення про серцево-судинний ризик остаточне?
DOI:
https://doi.org/10.24026/1818-1384.3(24).2008.118454Ключові слова:
pioglitazone, HOMA-IR index, high density lipoproteins, C-reactive proteinАнотація
Four month treatment with pioglitazone showed statistically relevant improvement of the certain list of markers: fasting glucose, HOMA-IR index, HbA1c. We speculate that descent of fasting glucose and C-peptide elevation may indicate peripheral improvement of insulin binding capacity since insulin concentration in blood circulation decreases. Treatment with pioglitazone showed its anti-atherosclerotic abilities by dyslipidemia improvement and by markedly decrease of the C-reactive protein, a strong predictor of cardiovascular events.Посилання
Ajjan R.A., Grant P.J. The cardiovascular safety of rosiglitazone // Expert Opin. Drug Saf. — 2008. — Vol. 7 (4).— P. 367-376.
Betz M.J., Shapiro I., Fassnacht M. et al. Peroxisome proliferator-activated receptor gamma agonists supress adrenocortical tumor cell proliferation and induce differentiation // Journal of Clinical Endocrinology & Metabolism. — 2005. — Vol. 90 (71). — P. 3886-3896.
Bloomgarden Z.T. Insulin resistance concepts // Diabetes Care. — 2007. — Vol. 30, Suppl. 5. — P. 1320-1326.
Hers M., Johns D., Reviriego Y. et al. A randomized, Double-Blind, Placebo-Controlled, Clinical Trial of the Effects of Pioglitazone on Glycemic Control and Dyslipidemia in Oral Antihyperglycemic Medication-Naive Patients with Type 2 Diabetes Mellitus // Clin. Ther. — 2003. — Vol. 25. — P. 1074-1095.
Masahiko I., Akihiko H., Hiroshi Y. et al. Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients // J. Atheroscler.Thromb. — 2008. — Vol. 15 — P. 34-40.
Matheus D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment : insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man // Diabetologia. — 1985. — Vol. 28. — Р. 412-419.
Mazzone T., Meyer P., Feinstein S. et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial // JAMA. — 2006. — Vol. 296 (21). — P. 2572-2581.
Nesto R.W., Bell D., Bonow R.O. et al. Thiazolodinedione use, fluid Retension, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association // Circulation. — 2003. — Vol. 108 (23) — P. 2941-2948.
Nissen S., Nicholls S., Steohen J. et al. Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes : The PERISCOPE Pandomized Controlled Trial // JAMA. — 2008. — Vol. 299, No13. — P. 1561-1573.
Principles and practice of endocrinology and metabolism / Edited by Kenneth L. Becker. — Philadelphia: Lippincot Williams & Wilkins, 2001. — 2477 p.
Ridker P.M., Rifal N., Rose L. et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in he prediction of first cardio-vascular events // N. Engl. J. Med. — 2002. — Vol. 347. — P. 1557-1565.
Sattar N. Predicting type 2 diabetes: a role for novel parameters or simple prediction models? // Clinical laboratory. — 2005. — Vol. 29, No2. — P. 7-11.
Sugamura K., Sugiyama S., Matsuzawa Y. et al. Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease // Circ. J. — 2008. — Vol. 72 (7). — P. 1193-1197.
Tanne J.N .FDA places "black box" warning on antidiabetes drugs // British Medical Journal — 2007. — Vol. 334 (7606) — P. 1237.
Wang C.H., Ting M.K., Verma S. et al. Pioglitazone increases the number and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus // American Heart Journal. — 2006. — Vol. 152(6). — P. 1051e1-1051e8.
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
